💥I’m Breaking Down Orakl Bio—Samsung’s Bold AI x RNA Power Play You Can’t Ignore

Your Weekly Shortcut to Deeptech Investing — Trends, Startup Intel & Investor Playbooks for VCs & Angels in 5 Minutes or Less

Mar 27, 2025

∙ Paid

A futuristic and high-tech image illustrating Samsung’s bold move into AI and RNA biotechnology with Orakl Bio. The scene features an advanced biotech lab with AI-powered robotic arms analyzing RNA sequences on a glowing holographic display. A financial analyst reviews stock market data on a transparent digital screen, highlighting Samsung’s investment strategy. The background includes a sleek research facility, futuristic medical breakthroughs, and data-driven biotech advancements. The color scheme combines deep blue, neon purple, and metallic silver, symbolizing cutting-edge technology and financial potential.

Let’s talk about Orakl Bio, a stealth-mode startup that’s stepping into the spotlight. Launched in Q1 2025 with $75 million in funding, Orakl is co-founded by Samsung and backed by SBV (Samsung’s biotech investment arm), alongside strategic investors from Korea and Europe. Their big idea? Using AI to turbocharge RNA therapeutics—think next-level drug design that could redefine medicine. With a stellar team, cutting-edge tech, and Samsung’s muscle behind them, Orakl’s got serious potential. But there are risks to weigh.

Here’s your full breakdown—packed with the latest insights—to help you decide if this is your next big win.

Keep reading with a 7-day free trial

Subscribe to Invest Deeptech to keep reading this post and get 7 days of free access to the full post archives.